By Application
Hot products 
-
Mouse Anti-ENO1 Recombinant Antibody (CBYC-A950) (CBMAB-A4388-YC)
-
Mouse Anti-A2M Recombinant Antibody (V2-178822) (CBMAB-A0036-YC)
-
Mouse Anti-APOH Recombinant Antibody (4D9A4) (CBMAB-A3249-YC)
-
Mouse Anti-CRTAM Recombinant Antibody (CBFYC-2235) (CBMAB-C2305-FY)
-
Mouse Anti-CDK7 Recombinant Antibody (CBYY-C1783) (CBMAB-C3221-YY)
-
Mouse Anti-F11R Recombinant Antibody (402) (CBMAB-0026-WJ)
-
Mouse Anti-ADGRE5 Recombinant Antibody (V2-360335) (CBMAB-C2088-CQ)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Mouse Anti-CASP8 Recombinant Antibody (CBYY-C0987) (CBMAB-C2424-YY)
-
Mouse Anti-ACVR1C Recombinant Antibody (V2-179685) (CBMAB-A1041-YC)
-
Mouse Anti-EIF4G1 Recombinant Antibody (2A9) (CBMAB-A2544-LY)
-
Mouse Anti-ABCA3 Recombinant Antibody (V2-178911) (CBMAB-A0145-YC)
-
Mouse Anti-COL1A2 Recombinant Antibody (CF108) (V2LY-1206-LY626)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
-
Mouse Anti-dsRNA Recombinant Antibody (2) (CBMAB-D1807-YC)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Mouse Anti-GDF5 Recombinant Antibody (1F4) (CBMAB-G2740-LY)
-
Rabbit Anti-ALK (Phosphorylated Y1278) Recombinant Antibody (D59G10) (PTM-CBMAB-0035YC)
-
Mouse Anti-GLP1R Recombinant Antibody (4F3) (CBMAB-G0521-LY)
-
Mouse Anti-AAV8 Recombinant Antibody (V2-634028) (CBMAB-AP022LY)
Cervical Cancer
Fig.1 Cervical cancer
Cervical cancer is a cancer originated from the cervix. Globally, cervical cancer is the fourth-most common cause of death from cancer among women and fourth-most common cause of cancer. At early stage, typically no symptoms are been found. However, later symptoms may include pelvic pain, vaginal bleeding, or pain during sexual intercourse. While bleeding after sex may not to be treated seriously, it may also reveal the presence of cervical cancer. Human papillomavirus (HPV) infection leads to about 90% of cases, followed by smoking. However, majority of people who have had HPV infections, do not develop cervical cancer. Cervical cancer typically develops from precancerous changes for 10 to 20 years. Around 90% of cervical cancer cases are diagnosed as squamous cell carcinomas, 10% are adenocarcinoma, and a small number are other types. Some novel prognostic markers, like TBLR1, MicroRNA-497, have been studied recently.
Loading...
Compare
